The following publication discusses the latest research regarding the Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis (NASH). Nature Medicine originally published this article, coauthored by ERG’s Vice President of Clinical Pharmacology Services Clay Dehn, on February 10th, 2022.
NAFLD is the most common form of chronic liver disease in the US. Find out if you’re at risk today by taking part in a clinical trial enrolling now.
Apply to participate in a study of an investigational pain medication following a knee replacement.
Are you a current smoker? You may qualify for a clinical trial evaluating various heated tobacco products.
